Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

After 11 years together my Volvo and I have reached the end of the road. But how do you get the best price for a second-hand ...

Två av Danmarks största företag drabbas av utvecklingen i USA. ”Det här ändrar omedelbart spelets regler”, säger analytiker.

Region Örebro län har problem med telefonin, skriver regionen på sin hemsida. Enligt Nerikes Allehanda ligger telefonin helt nere och alla anställda påverkas. Det går exempelvis inte att nå växeln på ...

Här är kvintetten av aktier som är i investerarnas blickfång när rapportfloden nu har rullat i gång i Europa. Den amerikanska ...

Danska läkemedelsjätten Novo Nordisk rasar med runt tio procent på Köpenhamnsbörsen. Orsaken är bland framför allt nya ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...